Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009499 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 1,131
- Enrollment target
- 20
- Study locations
NCT04009499: Active Phase 3 study of Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
NCT04009499 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 1,131 participants, above the 829-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04009499, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (20)
New York
- Pa0012 50010 - Brooklyn
- Pa0012 50011 - New York
- Pa0012 50034 - Rochester
Florida
- Pa0012 50033 - Palm Harbor
- Pa0012 50037 - Tampa
North Carolina
- Pa0012 50125 - Charlotte
- Pa0012 50031 - Salisbury
Arizona
- Pa0012 50017 - Phoenix
California
- Pa0012 50035 - San Diego
Georgia
- Pa0012 50039 - Atlanta
Idaho
- Pa0012 50024 - Boise
Kentucky
- Pa0012 50028 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,131 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2026-05-25 |
| Phase | Phase 3 |
What the registry record for NCT04009499 still lists
NCT04009499 is an interventional study that assigns participants to a tested intervention. Its 1,131 participants enrollment target places it among the larger protocols in the corpus, above the 829-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT04009499 names 20 study sites across 16 states, led by New York, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04009499 about?
NCT04009499 is a clinical study titled "A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
What is the current status of trial NCT04009499?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,131 participants. The study started on 2019-08-13. Estimated completion is 2026-05-25.
What conditions does trial NCT04009499 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT04009499?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04009499?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04009499 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04009499's enrollment target sits among peer trials
1,131 5th of 48 higher than 44 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI